 Serine Proteinase Inhibitors
"Serine Proteinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.
| Descriptor ID |
D015842
|
| MeSH Number(s) |
D27.505.519.389.745.800
|
| Concept/Terms |
Serine Proteinase Inhibitors- Serine Proteinase Inhibitors
- Serine Endopeptidase Inhibitors
- Serine Protease Inhibitors
- Serine Proteinase Antagonists
|
Below are MeSH descriptors whose meaning is more general than "Serine Proteinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Serine Proteinase Inhibitors".
This graph shows the total number of publications written about "Serine Proteinase Inhibitors" by people in this website by year, and whether "Serine Proteinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 1 | 1 | | 1990 | 0 | 1 | 1 | | 1995 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 0 | 2 | 2 | | 1998 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2003 | 1 | 1 | 2 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 1 | 2 | | 2007 | 0 | 1 | 1 | | 2008 | 1 | 2 | 3 | | 2009 | 0 | 2 | 2 | | 2012 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 2 | 1 | 3 | | 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Serine Proteinase Inhibitors" by people in Profiles.
-
Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
-
Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.
-
Cho L, Dent R, Stroes ESG, Stein EA, Sullivan D, Ruzza A, Flower A, Somaratne R, Rosenson RS. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. Cardiovasc Drugs Ther. 2018 08; 32(4):365-372.
-
Brandt EJ, Benes LB, Lee L, Dayspring TD, Sorrentino M, Davidson M. The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. J Cardiovasc Pharmacol Ther. 2019 01; 24(1):54-61.
-
Robinson JG, Davidson MH. Can We Cure Atherosclerosis? Rev Cardiovasc Med. 2018; 19(S1):S20-S24.
-
Roth EM, Davidson MH. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety. Rev Cardiovasc Med. 2018; 19(S1):S31-S46.
-
Briquez PS, Lorentz KM, Larsson HM, Frey P, Hubbell JA. Human Kunitz-type protease inhibitor engineered for enhanced matrix retention extends longevity of fibrin biomaterials. Biomaterials. 2017 Aug; 135:1-9.
-
Lee H, Ren J, Nocadello S, Rice AJ, Ojeda I, Light S, Minasov G, Vargas J, Nagarathnam D, Anderson WF, Johnson ME. Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Antiviral Res. 2017 Mar; 139:49-58.
-
Stein EA. What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management? Curr Opin Endocrinol Diabetes Obes. 2016 Apr; 23(2):97-105.
-
Stein EA. Low-density lipoprotein cholesterol reduction by inhibition of PCSK9. Curr Opin Lipidol. 2013 Dec; 24(6):510-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|